Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Akebia Therapeutics, Inc. on June 15, 2017. The filing details the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary events are the election of three directors to the Board of Directors for three-year terms expiring in 2020 and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. It is a procedural report of shareholder voting results.
Important Facts for Investors
- Shareholder Record Date: April 13, 2017, with 38,829,563 outstanding shares eligible to vote.
- Director Elections: John P. Butler, Muneer A. Satter, and Michael A. Wyzga were elected to the Board.
- Voting Results: Significant broker non-votes (12,163,493) were recorded for all director elections, though all candidates received majority support.
- Auditor Ratification: Ernst & Young LLP was ratified with 34,499,773 votes for, 31,639 against, and 21,715 abstentions.